IPCALAB Ltd.

949.7.00INR + 36.50 (+ 4.00%) VOLUME : 168000
    Average Volume
  • 5-Day 184,599.80
  • 20-Day 202,799.90
  • 3-Months 183,730.69

MARKET CLOSED

Price Table

Date Open High GREEN: if High is higher than last 2 days high
RED: if high is lower than last 2 days high
Low GREEN:if Low is higher than last 2 days low
RED: if low is lower than last 2 days low
LTP Close GREEN:if Day's Closing is near the Day's High
RED: if low is lower than last 2 days low
Volume Delivery % 20 Day SMA GREEN: if Day's Closing is above 20-Day SMA
RED: if Day's Closing is below 20-Day SMA
50 Day SMA GREEN: if Day's Closing is above 50-Day SMA
RED: if Day's Closing is below 50-Day SMA
100 Day SMA GREEN: if Day's Closing is above 100-Day SMA
RED: if Day's Closing is below 100-Day SMA
200 Day SMA GREEN: if Day's Closing is above 200-Day SMA
RED: if Day's Closing is below 200-Day SMA
18-Oct-19 915.00 954.00 915.00 949.70 946.70 168,190 74% 907.49 932.44 934.75 898.40
17-Oct-19 890.00 918.80 886.85 912.00 913.20 60,951 49% 907.55 932.87 934.52 897.67
16-Oct-19 884.90 897.55 877.10 894.40 892.30 71,159 59% 908.40 933.73 934.59 897.13
15-Oct-19 886.25 890.00 861.10 878.00 882.50 430,945 88% 911.11 935.07 934.99 896.59
14-Oct-19 864.00 894.30 856.75 893.80 890.05 191,908 50% 914.14 936.45 935.35 896.21
11-Oct-19 860.00 906.70 854.00 861.25 861.75 257,113 71% 916.87 937.59 935.55 895.65
10-Oct-19 864.15 869.90 844.65 858.10 856.50 566,790 94% 920.20 939.25 936.11 895.34

Performance

Key Data

Day High Low Range

Time Lowest Highest
10 AM 915.00 928.35
11 AM 915.00 939.00
12 PM 915.00 939.00
1 PM 915.00 939.00
2 PM 915.00 939.90

Company Profile - IPCALAB Ltd.

IPCALAB

In 1949, Ipca Laboratories Limited, which is a pharmaceutical company, was being incorporated. It was also promoted by a group of medical businessmen and professionals who were incorporated under the brand name 'The Indian Pharmaceutical Combine Association.' It is also a fully backward integrated, Indian pharmaceutical company with a robust thrust on exports. It is also the largest manufacturers of several APIs that they produce right from the primary stage. Both the APIs and Formulations are produced at the world-class manufacturing facilities. Leading drug regulatory authorities have approved these facilities - MHRA UK, US FDA, TGA Australia, WHO Geneva, HPFB Canada, WHO Geneva, MCC South Africa, PMDA Japan, KFDA Korea, EDQM and LAGeSO Berlin MOH. Currently, it is therapy leaders in both antimalarial as well as rheumatoid arthritis in the Indian market, along with a fast expanding presence in the global market as well. It has a brand leadersh ... ip in 4-5 therapeutic areas, for both the Formulations and APIs. Also, four of their major branded Formulations were ranked among the top 300 brands of India, and soon it emerged as one among the top exporters of APIs worldwide. It is also one of the biggest manufacturers in the world of APIs, and to name a few - Atenolol (Antihypertensive), Furosemide (Diuretic), Pyrantel Salts (Anthelmintic), Hydroxy Chloroquine Sulphate (NSAID), Chloroquine Phosphate (Antimalarial), Metoprolol Tartrate & Succinate (Antihypertensives). The Company is the largest supplier of such APIs and their intermediates world over. Their top 10 formulation brands are Zerodol (Aceclofenac and Combinations), Lariago (Chloroquine), HCQS (Hydroxychloroquine), Perinorm (Metoclopramide), Rapither (Artemotil), Tenoric (Chlorthalidone + Atenolol), Lumerax (Artemether + Lumefantrine), Etova (Etodolac), Malirid (Primaquine) and Folitrax (Methotrexate). With operations in over 110 countries across the globe, exports and domestic business account for the equal contribution of the company's income. Forbes, which is a leading US business magazine, selected Ipca in 2003, 2004, 2005 and 2007 among its top 200 successful, rising companies overseas, along with the sales under $1 Billion. Amongst several other Indian companies, only a few Indian Pharmaceutical companies are being featured in the Forbes list, and Ipca is one of them. It has also been awarded as 'Among the 100 Best Companies to Work in India' during the survey conducted for the 'India's Best Companies to Work For-2010'.

Some of the Group Companies:

Tonira
  • Tonira - Ankleshwar
  • Tonira - Nandesari

Some of the Products:

  1. APIs:It manufactures internationally known APIs, namely Atenolol (Antihypertensive), Chloroquine Phosphate (Antimalarial), Furosemide (Diuretic) and Pyrantel Salts (Anthelmintic). It also manufactures a range of drugs Intermediates.
  2. Formulations:It manufactures over 150 formulations catering in therapeutic and generic segments. These dosage forms are manufactured in tablets, capsules, oral liquids, dry powders for suspension, and injectable (liquid and dry).

Some of the Milestones:

  • 1976: It started the marketing of sugarcoated Chloroquine tablets, which was the first time in India.
  • 1978:
  • It introduced the formulations of Metoclopramide under the brand name 'Perinorm' for the first time in India.
  • It introduced 'Ipca Contact,' company's in-house Magazine.
  • 1994:
  • The Maiden Public Issue of shares.
  • It acquired an API manufacturing plant from BDH Pharmaceuticals (which is a subsidiary of E–Merck) located at Indore.
  • 1995: It commissioned a modern formulations plant located at Athal (Silvassa).
  • 1996: It also commissioned a new API R&D Centre located at Mumbai.
  • 1999: It was first to launch a formulation of Hydroxychloroquine Sulphate under the brand name 'HCQS' in India.
  • 2000: It received the ISO 9001 certification for the Ipca Athal formulations Plant.
  • 2001:
  • 'Trishul' the highest award was conferred on Ipca Laboratories Ltd. by CHEMEXIL (Basic Chemicals, Pharmaceuticals & Cosmetics Export Promotion Council) for outstanding export performance.
  • Launched new domestic marketing division - Innova, to promote specialty products in therapeutic segments of Psychiatry, Neurology, and Dermatology. Ipca acquired 'National Druggists (Pty) Ltd.' in South Africa.
  • Ipca Pharma Nigeria Ltd.' incorporated in Nigeria.
  • 2002:
  • Launched new domestic marketing division – Intima, to promote established brands with a focus on micro–interior marketing.
  • Wholly owned subsidiary 'Laboratories Ipca Do Brasil Ltd.' incorporated in Brazil.
  • 2003:
  • It introduced a new domestic marketing division- Activa that is dedicated to Rheumatology Care. Also, it is the first company in India to have such division for marketing super-specialty molecules.
  • But it started the new domestic marketing division such as, Hycare, which is dedicated to Cardio-Diabetology sections.
  • Forbes, which is a leading US business magazine, selected Ipca among its top 200 successful, rising companies outside the USA, with sales under $1 billion.
  • 2004:
  • Commissioned new Formulations are manufacturing plant at Silvassa.
  • Ipca Laboratories Ltd. received the 'Lifetime Achievement Award' for the year 2002-03 from CHEMEXIL (Pharmaceuticals & Cosmetics Export Promotion Council, Basic Chemicals) for the export promotion over the years.
  • 2005:
  • In August 2005, the Innotech Pharma Limited merged with the Ipca.
  • It also acquired cardiac brand Isordil from Wyeth Limited.
  • Forbes Asia, which is a leading US business magazine, chose Ipca, for the third consecutive year, among the first 200 'Best under a Billion Company' in Asia.
  • 2006:
  • It introduced a Fixed-dose ACT combination for the treatment of malaria and stopped the manufacturing of single-ingredient Oral Artemisinin derivatives.
  • It entered into a strategic alliance, along with Ranbaxy Pharmaceuticals Inc. for the U.S market.
  • Its new formulations plant located at Dehradun started operation on 5th May.
  • 2007:
  • October: Ipca Laboratories Ltd. was awarded by Forbes Inc., as one of the 'Best under a Billion' Forbes Global's 200 Best Small Companies, in the year 2007. In the past, it has received the same award for three consecutive years 2003, 2004 and 2005.
  • December: Also, Ipca - Ratlam received 2nd prize in the 'National Energy Conservation Award-2007' in the Drug and Pharmaceuticals sector, a part of the Bureau of Energy Efficiency that is under the Ministry of Power, Government of India, in New Delhi.
  • 2008:
  • August: Dr. Paul Bacon, a Professor Emeritus, University of Birmingham, the UK, which is a world-renowned authority in Rheumatoid arthritis, addressed several leading clinicians in six metro towns in India.
  • November: 'Ipca Contact' won Silver medal in ABCI's (or Association of Business Communicators of India) 48th annual Awards for the Excellence in Creative Business Communications.
  • December: Tonira Pharma's API manufacturing plants located at Ankleshwar and Nandesari received PMDA-Japan approval.
  • 2009:
  • November: Ipca - Ratlam celebrated the Silver Jubilee of its existence.
  • It received the IDMA's Quality Excellence Award 2009 - Silver Medal honored to Ipca - Dehradun plant.
  • Ipca - Dehradun formulations plant, also received an award for 'Energy Conservation' from the Uttrakhand Renewable Energy Development Agency (or UREDA) on the occasion of National Energy Conservation Day.
  • 2010:
  • November: 'Ipca Contact,' which is an in-house quarterly magazine won 'Bronze' medal in the Headline segment in ABCI 50th Awards Nite.
  • December: Ipca - Ratlam formulations plant ranked third position in the National Energy Conservation Award 2010.
  • Ipca: Dehradun formulation plant at Dehradun receives the 'Uttarakhand Energy Conservation Award 2010'. Ipca: Dehradun plant stood first in the entire State of Uttarakhand.
  • 2011:
  • It introduced Laxtaz, which is the new age laxative that combines Ispaghula, along with Lactitol.
  • It introduced new division Ipca-Dynamix, which caters to gastrointestinal, cardiovascular, antibacterial, respiratory sections.
  • It introduced Rapiclav®1g in West African countries of Ivory Coast, Senegal, Mali, Burkina Faso, Benin, and Nigeria.
  • 2013:
  • It received the 'Corporate Citizen Award' for the best corporate governance practice.